In my twenty-two years of practicing medicine, I have observed the evolution of genomic testing and its increasing utility in oncology.
Study shows DNA biomarker can be used to predict outcomes for high risk low grade gliomas
In the spring of 2001, I visited a longtime friend and collaborator, Alexandre Barbault, to share with him my vision of using low levels radiofrequency electromagnetic fields for the treatment of cancer.
Anne-Marie Langevin, of the South Texas Pediatric Minority/Underserved NCI Community Oncology Research Program site in San Antonio, won the 2018 Harry Hynes Award, which is given annually to the PI who reflects the outstanding contribution to clinical trials and community research.
Historically, oncology drug development has evolved on what may seem to be a different planet, at least relative to mainstream clinical pharmacology.
The Cancer Letter won four 2018 Dateline Awards from the Washington, D.C. Chapter of the Society of Professional Journalists:
To the Editor:One of the biggest questions that early-stage breast cancer patients face is whether they will benefit from chemotherapy treatment. Two large scale randomized clinical trials that implement genomic testing have positively addressed this question.
I remember the day I met Margaret “Peg” Geisler, who has now been living with breast cancer for 40 years, and with metastatic disease for 36 of those years.
In its just-published guideline on screening for colorectal cancer, the American Cancer Society revised its 2008 CRC screening guidelines, recommending that screening begin at age 45 instead of 50.
Finasteride, a common hormone-blocking drug, reduces men's risk of getting prostate cancer without increasing their risk of dying from the disease, according to long-term follow-up data.
